| Shamai A Grossman, MD | |
|
1 Deaconess Rd, Wcc2, Boston, MA 02215-5321 | |
| (617) 754-2331 | |
| Not Available |
| Full Name | Shamai A Grossman |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 35 Years |
| Location | 1 Deaconess Rd, Boston, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205877834 | NPI | - | NPPES |
| 110057922A | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 79995 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beth Israel Deaconess Medical Center | Boston, MA | Hospital |
| Beth Israel Deaconess Hospital - Needham | Needham, MA | Hospital |
| Northeast Hospital Corporation | Beverly, MA | Hospital |
| South Shore Hospital | South weymouth, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc | 4486567104 | 1344 |
| Coastal Medical Associates | 7113029257 | 412 |
| Beth Israel Deaconess Medical Center Inc | 8123936119 | 83 |
News Archive
Joseph Boscarino, Ph.D, M.P.H.,will be recognized by the International Society of Traumatic Stress (ISTSS) with a Lifetime Achievement Award for his contributions to the research of traumatic stress.
Researchers have found long-sought genes in the sensory hair cells of the inner ear that, when mutated, prevent sound waves from being converted to electric signals - a fundamental first step in hearing. The team, co-led by Jeffrey Holt, PhD, in the department of otolaryngology at Children-s Hospital Boston, and Andrew Griffith, MD, PhD, of the NIH-s National Institute on Deafness and other Communication Disorders (NIDCD), then restored these electrical signals in the sensory cells of deaf mice by introducing normal genes.
Inherited diseases such as cystic fibrosis can be caused by genetic "nonsense mutations" that disrupt the way human cells make proteins. David Bedwell, Ph.D., a professor in the University of Alabama at Birmingham Department of Microbiology, says scientists are now closer to producing drugs that will fix this disruption and drastically improve treatment of genetic disease.
News outlets explore the challenges states face as they increasingly try to move recipients into managed care plans in order to control costs and brace for upcoming expansions.
Curis, Inc. a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has initiated a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor, as a single-agent therapy for patients with operable basal cell carcinoma (BCC).
› Verified 1 days ago
| Entity Name | Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316987993 PECOS PAC ID: 4486567104 Enrollment ID: O20040105000227 |
News Archive
Joseph Boscarino, Ph.D, M.P.H.,will be recognized by the International Society of Traumatic Stress (ISTSS) with a Lifetime Achievement Award for his contributions to the research of traumatic stress.
Researchers have found long-sought genes in the sensory hair cells of the inner ear that, when mutated, prevent sound waves from being converted to electric signals - a fundamental first step in hearing. The team, co-led by Jeffrey Holt, PhD, in the department of otolaryngology at Children-s Hospital Boston, and Andrew Griffith, MD, PhD, of the NIH-s National Institute on Deafness and other Communication Disorders (NIDCD), then restored these electrical signals in the sensory cells of deaf mice by introducing normal genes.
Inherited diseases such as cystic fibrosis can be caused by genetic "nonsense mutations" that disrupt the way human cells make proteins. David Bedwell, Ph.D., a professor in the University of Alabama at Birmingham Department of Microbiology, says scientists are now closer to producing drugs that will fix this disruption and drastically improve treatment of genetic disease.
News outlets explore the challenges states face as they increasingly try to move recipients into managed care plans in order to control costs and brace for upcoming expansions.
Curis, Inc. a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has initiated a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor, as a single-agent therapy for patients with operable basal cell carcinoma (BCC).
› Verified 1 days ago
| Entity Name | South Shore Hospital Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134227606 PECOS PAC ID: 4385546217 Enrollment ID: O20040122000304 |
News Archive
Joseph Boscarino, Ph.D, M.P.H.,will be recognized by the International Society of Traumatic Stress (ISTSS) with a Lifetime Achievement Award for his contributions to the research of traumatic stress.
Researchers have found long-sought genes in the sensory hair cells of the inner ear that, when mutated, prevent sound waves from being converted to electric signals - a fundamental first step in hearing. The team, co-led by Jeffrey Holt, PhD, in the department of otolaryngology at Children-s Hospital Boston, and Andrew Griffith, MD, PhD, of the NIH-s National Institute on Deafness and other Communication Disorders (NIDCD), then restored these electrical signals in the sensory cells of deaf mice by introducing normal genes.
Inherited diseases such as cystic fibrosis can be caused by genetic "nonsense mutations" that disrupt the way human cells make proteins. David Bedwell, Ph.D., a professor in the University of Alabama at Birmingham Department of Microbiology, says scientists are now closer to producing drugs that will fix this disruption and drastically improve treatment of genetic disease.
News outlets explore the challenges states face as they increasingly try to move recipients into managed care plans in order to control costs and brace for upcoming expansions.
Curis, Inc. a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has initiated a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor, as a single-agent therapy for patients with operable basal cell carcinoma (BCC).
› Verified 1 days ago
| Entity Name | Associated Physicians Of Harvard Medical Faculty Physicians At Beth Is |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952358533 PECOS PAC ID: 6305749987 Enrollment ID: O20040130000354 |
News Archive
Joseph Boscarino, Ph.D, M.P.H.,will be recognized by the International Society of Traumatic Stress (ISTSS) with a Lifetime Achievement Award for his contributions to the research of traumatic stress.
Researchers have found long-sought genes in the sensory hair cells of the inner ear that, when mutated, prevent sound waves from being converted to electric signals - a fundamental first step in hearing. The team, co-led by Jeffrey Holt, PhD, in the department of otolaryngology at Children-s Hospital Boston, and Andrew Griffith, MD, PhD, of the NIH-s National Institute on Deafness and other Communication Disorders (NIDCD), then restored these electrical signals in the sensory cells of deaf mice by introducing normal genes.
Inherited diseases such as cystic fibrosis can be caused by genetic "nonsense mutations" that disrupt the way human cells make proteins. David Bedwell, Ph.D., a professor in the University of Alabama at Birmingham Department of Microbiology, says scientists are now closer to producing drugs that will fix this disruption and drastically improve treatment of genetic disease.
News outlets explore the challenges states face as they increasingly try to move recipients into managed care plans in order to control costs and brace for upcoming expansions.
Curis, Inc. a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has initiated a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor, as a single-agent therapy for patients with operable basal cell carcinoma (BCC).
› Verified 1 days ago
| Entity Name | Northeast Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316917941 PECOS PAC ID: 1153213202 Enrollment ID: O20040721000148 |
News Archive
Joseph Boscarino, Ph.D, M.P.H.,will be recognized by the International Society of Traumatic Stress (ISTSS) with a Lifetime Achievement Award for his contributions to the research of traumatic stress.
Researchers have found long-sought genes in the sensory hair cells of the inner ear that, when mutated, prevent sound waves from being converted to electric signals - a fundamental first step in hearing. The team, co-led by Jeffrey Holt, PhD, in the department of otolaryngology at Children-s Hospital Boston, and Andrew Griffith, MD, PhD, of the NIH-s National Institute on Deafness and other Communication Disorders (NIDCD), then restored these electrical signals in the sensory cells of deaf mice by introducing normal genes.
Inherited diseases such as cystic fibrosis can be caused by genetic "nonsense mutations" that disrupt the way human cells make proteins. David Bedwell, Ph.D., a professor in the University of Alabama at Birmingham Department of Microbiology, says scientists are now closer to producing drugs that will fix this disruption and drastically improve treatment of genetic disease.
News outlets explore the challenges states face as they increasingly try to move recipients into managed care plans in order to control costs and brace for upcoming expansions.
Curis, Inc. a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has initiated a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor, as a single-agent therapy for patients with operable basal cell carcinoma (BCC).
› Verified 1 days ago
| Entity Name | Beth Israel Deaconess Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548202641 PECOS PAC ID: 8123936119 Enrollment ID: O20041001000827 |
News Archive
Joseph Boscarino, Ph.D, M.P.H.,will be recognized by the International Society of Traumatic Stress (ISTSS) with a Lifetime Achievement Award for his contributions to the research of traumatic stress.
Researchers have found long-sought genes in the sensory hair cells of the inner ear that, when mutated, prevent sound waves from being converted to electric signals - a fundamental first step in hearing. The team, co-led by Jeffrey Holt, PhD, in the department of otolaryngology at Children-s Hospital Boston, and Andrew Griffith, MD, PhD, of the NIH-s National Institute on Deafness and other Communication Disorders (NIDCD), then restored these electrical signals in the sensory cells of deaf mice by introducing normal genes.
Inherited diseases such as cystic fibrosis can be caused by genetic "nonsense mutations" that disrupt the way human cells make proteins. David Bedwell, Ph.D., a professor in the University of Alabama at Birmingham Department of Microbiology, says scientists are now closer to producing drugs that will fix this disruption and drastically improve treatment of genetic disease.
News outlets explore the challenges states face as they increasingly try to move recipients into managed care plans in order to control costs and brace for upcoming expansions.
Curis, Inc. a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has initiated a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor, as a single-agent therapy for patients with operable basal cell carcinoma (BCC).
› Verified 1 days ago
| Entity Name | Northeast Medical Practice Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235147760 PECOS PAC ID: 2365405024 Enrollment ID: O20050111000265 |
News Archive
Joseph Boscarino, Ph.D, M.P.H.,will be recognized by the International Society of Traumatic Stress (ISTSS) with a Lifetime Achievement Award for his contributions to the research of traumatic stress.
Researchers have found long-sought genes in the sensory hair cells of the inner ear that, when mutated, prevent sound waves from being converted to electric signals - a fundamental first step in hearing. The team, co-led by Jeffrey Holt, PhD, in the department of otolaryngology at Children-s Hospital Boston, and Andrew Griffith, MD, PhD, of the NIH-s National Institute on Deafness and other Communication Disorders (NIDCD), then restored these electrical signals in the sensory cells of deaf mice by introducing normal genes.
Inherited diseases such as cystic fibrosis can be caused by genetic "nonsense mutations" that disrupt the way human cells make proteins. David Bedwell, Ph.D., a professor in the University of Alabama at Birmingham Department of Microbiology, says scientists are now closer to producing drugs that will fix this disruption and drastically improve treatment of genetic disease.
News outlets explore the challenges states face as they increasingly try to move recipients into managed care plans in order to control costs and brace for upcoming expansions.
Curis, Inc. a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has initiated a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor, as a single-agent therapy for patients with operable basal cell carcinoma (BCC).
› Verified 1 days ago
| Entity Name | Coastal Medical Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932175684 PECOS PAC ID: 7113029257 Enrollment ID: O20070221000057 |
News Archive
Joseph Boscarino, Ph.D, M.P.H.,will be recognized by the International Society of Traumatic Stress (ISTSS) with a Lifetime Achievement Award for his contributions to the research of traumatic stress.
Researchers have found long-sought genes in the sensory hair cells of the inner ear that, when mutated, prevent sound waves from being converted to electric signals - a fundamental first step in hearing. The team, co-led by Jeffrey Holt, PhD, in the department of otolaryngology at Children-s Hospital Boston, and Andrew Griffith, MD, PhD, of the NIH-s National Institute on Deafness and other Communication Disorders (NIDCD), then restored these electrical signals in the sensory cells of deaf mice by introducing normal genes.
Inherited diseases such as cystic fibrosis can be caused by genetic "nonsense mutations" that disrupt the way human cells make proteins. David Bedwell, Ph.D., a professor in the University of Alabama at Birmingham Department of Microbiology, says scientists are now closer to producing drugs that will fix this disruption and drastically improve treatment of genetic disease.
News outlets explore the challenges states face as they increasingly try to move recipients into managed care plans in order to control costs and brace for upcoming expansions.
Curis, Inc. a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has initiated a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor, as a single-agent therapy for patients with operable basal cell carcinoma (BCC).
› Verified 1 days ago
| Entity Name | Associated Physicians Of Harvard Medical Faculty Physicians At Beth Is |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952358533 PECOS PAC ID: 6305749987 Enrollment ID: O20130606000720 |
News Archive
Joseph Boscarino, Ph.D, M.P.H.,will be recognized by the International Society of Traumatic Stress (ISTSS) with a Lifetime Achievement Award for his contributions to the research of traumatic stress.
Researchers have found long-sought genes in the sensory hair cells of the inner ear that, when mutated, prevent sound waves from being converted to electric signals - a fundamental first step in hearing. The team, co-led by Jeffrey Holt, PhD, in the department of otolaryngology at Children-s Hospital Boston, and Andrew Griffith, MD, PhD, of the NIH-s National Institute on Deafness and other Communication Disorders (NIDCD), then restored these electrical signals in the sensory cells of deaf mice by introducing normal genes.
Inherited diseases such as cystic fibrosis can be caused by genetic "nonsense mutations" that disrupt the way human cells make proteins. David Bedwell, Ph.D., a professor in the University of Alabama at Birmingham Department of Microbiology, says scientists are now closer to producing drugs that will fix this disruption and drastically improve treatment of genetic disease.
News outlets explore the challenges states face as they increasingly try to move recipients into managed care plans in order to control costs and brace for upcoming expansions.
Curis, Inc. a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has initiated a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor, as a single-agent therapy for patients with operable basal cell carcinoma (BCC).
› Verified 1 days ago
| Entity Name | South Shore Health Express Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477044212 PECOS PAC ID: 6406108836 Enrollment ID: O20181115000152 |
News Archive
Joseph Boscarino, Ph.D, M.P.H.,will be recognized by the International Society of Traumatic Stress (ISTSS) with a Lifetime Achievement Award for his contributions to the research of traumatic stress.
Researchers have found long-sought genes in the sensory hair cells of the inner ear that, when mutated, prevent sound waves from being converted to electric signals - a fundamental first step in hearing. The team, co-led by Jeffrey Holt, PhD, in the department of otolaryngology at Children-s Hospital Boston, and Andrew Griffith, MD, PhD, of the NIH-s National Institute on Deafness and other Communication Disorders (NIDCD), then restored these electrical signals in the sensory cells of deaf mice by introducing normal genes.
Inherited diseases such as cystic fibrosis can be caused by genetic "nonsense mutations" that disrupt the way human cells make proteins. David Bedwell, Ph.D., a professor in the University of Alabama at Birmingham Department of Microbiology, says scientists are now closer to producing drugs that will fix this disruption and drastically improve treatment of genetic disease.
News outlets explore the challenges states face as they increasingly try to move recipients into managed care plans in order to control costs and brace for upcoming expansions.
Curis, Inc. a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has initiated a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor, as a single-agent therapy for patients with operable basal cell carcinoma (BCC).
› Verified 1 days ago
| Entity Name | Bid-milton Physician Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164060778 PECOS PAC ID: 7416375399 Enrollment ID: O20200909000678 |
News Archive
Joseph Boscarino, Ph.D, M.P.H.,will be recognized by the International Society of Traumatic Stress (ISTSS) with a Lifetime Achievement Award for his contributions to the research of traumatic stress.
Researchers have found long-sought genes in the sensory hair cells of the inner ear that, when mutated, prevent sound waves from being converted to electric signals - a fundamental first step in hearing. The team, co-led by Jeffrey Holt, PhD, in the department of otolaryngology at Children-s Hospital Boston, and Andrew Griffith, MD, PhD, of the NIH-s National Institute on Deafness and other Communication Disorders (NIDCD), then restored these electrical signals in the sensory cells of deaf mice by introducing normal genes.
Inherited diseases such as cystic fibrosis can be caused by genetic "nonsense mutations" that disrupt the way human cells make proteins. David Bedwell, Ph.D., a professor in the University of Alabama at Birmingham Department of Microbiology, says scientists are now closer to producing drugs that will fix this disruption and drastically improve treatment of genetic disease.
News outlets explore the challenges states face as they increasingly try to move recipients into managed care plans in order to control costs and brace for upcoming expansions.
Curis, Inc. a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has initiated a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor, as a single-agent therapy for patients with operable basal cell carcinoma (BCC).
› Verified 1 days ago
| Entity Name | Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538774443 PECOS PAC ID: 4486567104 Enrollment ID: O20201029002622 |
News Archive
Joseph Boscarino, Ph.D, M.P.H.,will be recognized by the International Society of Traumatic Stress (ISTSS) with a Lifetime Achievement Award for his contributions to the research of traumatic stress.
Researchers have found long-sought genes in the sensory hair cells of the inner ear that, when mutated, prevent sound waves from being converted to electric signals - a fundamental first step in hearing. The team, co-led by Jeffrey Holt, PhD, in the department of otolaryngology at Children-s Hospital Boston, and Andrew Griffith, MD, PhD, of the NIH-s National Institute on Deafness and other Communication Disorders (NIDCD), then restored these electrical signals in the sensory cells of deaf mice by introducing normal genes.
Inherited diseases such as cystic fibrosis can be caused by genetic "nonsense mutations" that disrupt the way human cells make proteins. David Bedwell, Ph.D., a professor in the University of Alabama at Birmingham Department of Microbiology, says scientists are now closer to producing drugs that will fix this disruption and drastically improve treatment of genetic disease.
News outlets explore the challenges states face as they increasingly try to move recipients into managed care plans in order to control costs and brace for upcoming expansions.
Curis, Inc. a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has initiated a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor, as a single-agent therapy for patients with operable basal cell carcinoma (BCC).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Shamai A Grossman, MD 1 Deaconess Rd, Wcc2, Boston, MA 02215-5321 Ph: (617) 754-2331 | Shamai A Grossman, MD 1 Deaconess Rd, Wcc2, Boston, MA 02215-5321 Ph: (617) 754-2331 |
News Archive
Joseph Boscarino, Ph.D, M.P.H.,will be recognized by the International Society of Traumatic Stress (ISTSS) with a Lifetime Achievement Award for his contributions to the research of traumatic stress.
Researchers have found long-sought genes in the sensory hair cells of the inner ear that, when mutated, prevent sound waves from being converted to electric signals - a fundamental first step in hearing. The team, co-led by Jeffrey Holt, PhD, in the department of otolaryngology at Children-s Hospital Boston, and Andrew Griffith, MD, PhD, of the NIH-s National Institute on Deafness and other Communication Disorders (NIDCD), then restored these electrical signals in the sensory cells of deaf mice by introducing normal genes.
Inherited diseases such as cystic fibrosis can be caused by genetic "nonsense mutations" that disrupt the way human cells make proteins. David Bedwell, Ph.D., a professor in the University of Alabama at Birmingham Department of Microbiology, says scientists are now closer to producing drugs that will fix this disruption and drastically improve treatment of genetic disease.
News outlets explore the challenges states face as they increasingly try to move recipients into managed care plans in order to control costs and brace for upcoming expansions.
Curis, Inc. a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has initiated a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor, as a single-agent therapy for patients with operable basal cell carcinoma (BCC).
› Verified 1 days ago
Yeu-shin Cindy Chang, M.D., M.P.H. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Bwh Dept. Of Emergency Medicine, Boston, MA 02115 Phone: 617-732-8070 | |
Lorenzo Albala, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 55 Fruit St, Boston, MA 02114 Phone: 617-724-4068 | |
Dr. Jacob Ari Hurwitz, MD MPH Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 55 Fruit St, Boston, MA 02114 Phone: 617-724-4068 | |
Christopher Lites, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 330 Brookline Ave, Boston, MA 02215 Phone: 617-667-7000 | |
Aneesh T Narang, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1 Boston Medical Ctr Pl, Dowling 1 South, Boston, MA 02118 Phone: 617-414-5481 Fax: 617-414-7759 | |
Dr. Justin Thomas Pitman, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Neville House - 236a, Boston, MA 02115 Phone: 617-732-8070 | |
Dr. Nadine Youssef, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 750 Washington St, Box 311 / Department Of Emergency Medicine, Boston, MA 02111 Phone: 617-636-4723 |